Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC with or without Radiotherapy for Solid Tumors
NCT02819843Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2016
- Primary completion
- Feb 2024
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec in melanoma, Merkel cell carcinoma (MCC), solid tumor, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2016; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanomaMerkel cell carcinoma (MCC)solid tumor
Beyond the preview
Go deeper on NCT02819843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02819843.